found glp 1 GLP-1 meds slow cancer progression in new Cleveland Clinic study | Cleveland Clinic posted on the topic How Three Types of GLP-1

The SELECT trial, which included patients with CV disease and overweight or obesity (many also had increased risk for diabetes), showed a reduction in major adverse CV events (defined as CV death, nonfatal heart attack, and nonfatal stroke) of 20% with weekly subcutaneous semaglutide 2.4 mg

71 In addition, the length of exposure to GLP1RA could have been insufficient to detect some longerterm effects, increasing the chance of falsely negative results

Your prescription must be written specifically for Wegovy or Ozempic, since a compounded Rx is not transferable

For a deeper look at how semaglutide, a GLP-1 receptor agonist, compares to tirzepatide, a dual GLP-1 and GIP receptor agonist, read our comparison guide on semaglutide vs